keyword
https://read.qxmd.com/read/32781263/efficacy-and-safety-of-sintilimab-plus-pemetrexed-and-platinum-as-first-line-treatment-for-locally-advanced-or-metastatic-nonsquamous-non-small-cell-lung-cancer-a-randomized-double-blind-phase-3-study-orient-11
#1
Yunpeng Yang, Zhehai Wang, Jian Fang, Qitao Yu, Baohui Han, Shundong Cang, Gongyan Chen, Xiaodong Mei, Zhixiong Yang, Rui Ma, Minghong Bi, Xiubao Ren, Jianying Zhou, Baolan Li, Yong Song, Jifeng Feng, Juan Li, Zhiyong He, Rui Zhou, Weimin Li, You Lu, Yingyi Wang, Lijun Wang, Nong Yang, Yan Zhang, Zhuang Yu, Yanqiu Zhao, Conghua Xie, Ying Cheng, Hui Zhou, Shuyan Wang, Donglei Zhu, Wen Zhang, Li Zhang
INTRODUCTION: Sintilimab, an anti-programmed death 1 antibody, plus pemetrexed and platinum had shown promising efficacy for nonsquamous non-small cell lung cancer in a phase 1b study. We conducted a randomized, double-blind, phase 3 study to compare the efficacy and safety of sintilimab with placebo, both in combination with such chemotherapy. (ClinicalTrials.gov: NCT03607539) METHODS: A total of 397 patients with previously untreated locally advanced or metastatic nonsquamous NSCLC without sensitizing epidermal growth factor receptor or anaplastic lymphoma kinase genomic aberration were randomized (2:1 ratio) to receive either sintilimab 200 mg or placebo plus pemetrexed and platinum Q3W for 4 cycles, followed by sintilimab or placebo plus pemetrexed therapy...
July 31, 2020: Journal of Thoracic Oncology
https://read.qxmd.com/read/32781247/low-dose-hypofractionated-total-skin-electron-beam-therapy-for-adult-cutaneous-t-cell-lymphoma
#2
Elizabeth B Jeans, Yue-Houng Hu, Bradley J Stish, Brian King, Mark Davis, William S Harmsen, Kristin M Fruth, Sarah E Locher, Christopher L Deufel, Jaden D Evans, James A Martenson, Scott C Lester
OBJECTIVES: Historically, the standard of care for total skin electron beam therapy (TSEBT) delivered 30-36 Gray (Gy) over 5-10 weeks. Given the high-risk of relapse, a majority of patients require additional treatments. Therefore, attempts to utilize a shortened course of TSEBT have been investigated. METHODS: We conducted a single-institution retrospective review to evaluate disease response, control, and toxicity using a low-dose, hypofractionated course of TSEBT (HTSEBT) in patients with mycosis fungoides...
August 8, 2020: Practical Radiation Oncology
https://read.qxmd.com/read/32781214/myd88-l265p-mutation-detected-by-digital-pcr-as-a-prognostic-factor-in-patients-with-diffuse-large-b-cell-lymphoma-in-rituximab-era
#3
Noriko Nishimura, Kengo Takeuchi, Reimi Asaka, Naoko Tuyama, Norihito Inoue, Yoshiharu Kusano, Yuko Mishima, Masahiro Yokoyama, Yasuhito Terui
The central nervous system (CNS) relapse in patients with diffuse large B cell lymphoma (DLBCL) is fatal as there are no effective rescue treatments. To test if the presence of the MYD88 L265P mutation is a prognostic factor for secondary CNS relapse, we carried out the digital PCR analysis of 134 samples from patients with DLBCL at diagnosis. The MYD88 L265P mutations were detected in 22 (16.4%) patients, particularly in those with a non-GC subtype, CD5-positive, high absolute monocyte count, extra-nodal lymphoma, and B symptoms...
July 24, 2020: Leukemia Research
https://read.qxmd.com/read/32780847/molecular-background-delineates-outcome-of-double-protein-expressor-diffuse-large-b-cell-lymphoma
#4
Leo Meriranta, Annika Pasanen, Amjad Alkodsi, Jari Haukka, Marja-Liisa Karjalainen-Lindsberg, Sirpa Leppä
Concomitant deregulation of MYC and BCL2 comprises clinically significant, yet poorly characterized biological high-risk feature in diffuse large B-cell lymphoma (DLBCL). To interrogate these lymphomas, we analyzed translocations and protein expression of BCL2, BCL6, and MYC; correlated the findings with comprehensive mutational, transcriptomic, and clinical data in 181 patients with primary DLBCL; and validated the key findings in independent data sets. Structural variations of BCL2 were subtype-specific and specifically increased BCL2 expression...
August 11, 2020: Blood Advances
https://read.qxmd.com/read/32780846/hematopoietic-recovery-in-patients-receiving-chimeric-antigen-receptor-t-cell-therapy-for-hematologic-malignancies
#5
Tania Jain, Andrea Knezevic, Martina Pennisi, Yunxin Chen, Josel D Ruiz, Terence J Purdon, Sean M Devlin, Melody Smith, Gunjan L Shah, Elizabeth Halton, Claudia Diamonte, Michael Scordo, Craig S Sauter, Elena Mead, Bianca D Santomasso, M Lia Palomba, Connie W Batlevi, Molly A Maloy, Sergio Giralt, Eric Smith, Renier Brentjens, Jae H Park, Miguel-Angel Perales, Sham Mailankody
Factors contributing to hematopoietic recovery following chimeric antigen receptor (CAR) T-cell therapy have not been well studied. In an analysis of 83 patients with hematologic malignancies treated with CAR T-cell therapy, we describe patterns of hematopoietic recovery and evaluate potentially associated factors. We included patients who received axicabtagene ciloleucel (n = 30) or tisagenlecleucel (n = 10) for B-cell lymphoma, CD19-28z CAR T therapy for B-cell acute lymphoblastic leukemia (NCT01044069; n = 37), or B-cell maturation antigen targeting CAR T cells for multiple myeloma (NCT03070327; n = 6)...
August 11, 2020: Blood Advances
https://read.qxmd.com/read/32780660/brigatinib-versus-crizotinib-in-advanced-alk-inhibitor-naive-alk-positive-non-small-cell-lung-cancer-second-interim-analysis-of-the-phase-iii-alta-1l-trial
#6
D Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, James C H Yang, Ji-Youn Han, Maximilian J Hochmair, Ki Hyeong Lee, Angelo Delmonte, Maria Rosario García Campelo, Dong-Wan Kim, Frank Griesinger, Enriqueta Felip, Raffaele Califano, Alexander Spira, Scott N Gettinger, Marcello Tiseo, Huamao M Lin, Neeraj Gupta, Michael J Hanley, Quanhong Ni, Pingkuan Zhang, Sanjay Popat
PURPOSE: Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, demonstrated superior progression-free survival (PFS) and improved health-related quality of life (QoL) versus crizotinib in advanced ALK inhibitor-naive ALK-positive non-small cell lung cancer (NSCLC) at first interim analysis (99 events; median brigatinib follow-up, 11.0 months) in the open-label, phase III ALTA-1L trial (ClinicalTrials.gov identifier: NCT02737501). We report results of the second prespecified interim analysis (150 events)...
August 11, 2020: Journal of Clinical Oncology
https://read.qxmd.com/read/32780608/cost-utility-analysis-of-tisagenlecleucel-vs-salvage-chemotherapy-in-the-treatment-of-relapsed-refractory-diffuse-large-b-cell-lymphoma-from-singapore-s-healthcare-system-perspective
#7
Boon Piang Cher, Kar Yee Gan, Mohamed Ismail Abdul Aziz, Liang Lin, William Ying Khee Hwang, Li Mei Poon, Kwong Ng
Background: Patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) have limited treatment options and poor prognoses. Tisagenlecleucel, a chimeric antigen receptor (CAR) T-cell therapy has shown early promise in improving survival outcomes, but at a high upfront cost. This study evaluated the cost-effectiveness of tisagenlecleucel versus salvage chemotherapy for treating patients with r/r DLBCL who have failed at least 2 lines of systemic therapies. Methods: A hybrid decision tree and three-state partitioned survival model (progression-free (PF), progressive disease and death) was developed from the Singapore healthcare payer perspective...
August 11, 2020: Journal of Medical Economics
https://read.qxmd.com/read/32780548/alantolactone-induces-apoptosis-in-thp-1-cells-through-stat3-survivin-inhibition-and-intrinsic-apoptosis-pathway
#8
Bashir Ahmad, Yaser Gamallat, Pengyu Su, Akbar Husain, Ata Ur Rehman, Mohamed Y Zaky, Ahmed Musa Hago Bakheet, Naeem Tahir, Yi Xin, Wang Liang
Cancer is the second foremost cause of mortality in the world, and THP-1 cells play an important role in cancer progression. Alantolactone (ALT), a sesquiterpene lactone compound derived from Inula helenium, has a number of biological activities including antibacterial, antifungal, and anticancer. The current study was conducted to investigate the effects of ALT on THP-1 cells and its underlying molecular mechanisms. THP-1 cells were cultured and treated with ALT (20, 40 µM) for 12 h, and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, cell morphology, live/dead, and apoptosis assays were performed...
August 11, 2020: Chemical Biology & Drug Design
https://read.qxmd.com/read/32779901/-hemophagocytic-lymphohistiocytosis-on-epstein-barr-virus-reactivation
#9
C Van Severen, A Jaspers, T Weber, M Gustin
We describe the case of a 43-years-old female patient admitted in the emergency department for impairment of general condition and dyspnea. This patient is on immunosuppressive medication for Behçet's disease and will develop a lymphoma and hemophagocytic lymphohistiocytosis following Epstein-Barr virus (EBV) reactivation. This clinical case introduces a brief literature review about hemophagocytic lymphohistiocytosis (HLH).
July 2020: Revue Médicale de Liège
https://read.qxmd.com/read/32779819/effect-of-simvastatin-on-cell-proliferation-and-ras-activation-in-canine-tumour-cells
#10
Kosuke Kobayashi, Kenji Baba, Satoshi Kambayashi, Masaru Okuda
Statins are inhibitors of the mevalonate cascade that is responsible for cholesterol biosynthesis and the formation of intermediate metabolites, farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) used in the prenylation of proteins. Although statins are widely used in the treatment of hypercholesterolemia, recent studies suggest that they also inhibit proliferation of tumour cells by reducing prenylation of small GTP-binding proteins, such as Ras. This study aimed to evaluate the effect of simvastatin on cell proliferation and Ras activation in various canine tumour cell lines, including hemangiosarcoma (HSA), melanoma, and lymphoma cell lines...
August 11, 2020: Veterinary and Comparative Oncology
https://read.qxmd.com/read/32779796/treatment-and-prognosis-of-primary-pulmonary-lymphoma-a-long-term-follow-up-study
#11
Michelina Santopietro, Sofia Kovalchuk, Roberta Battistini, Benedetta Puccini, Ombretta Annibali, Ilaria Romano, Valerio Zoli, Giuseppe Avvisati, Alberto Bosi, Luigi Rigacci
Primary pulmonary lymphoma (PPL) is a rare disease with not well-defined optimal treatment. Outcomes and follow-up are variable in published data. OBJECTIVES: To define the outcome and optimal treatment strategies in PPL. METHODS: We reviewed the medical records of 49 patients with PPL treated in three Italian Hematological Institutions between 2002 and 2018. RESULTS: Thirty-eight (77.5%) cases were indolent-PPL and 11 (22.5%) cases were aggressive-PPL...
August 11, 2020: European Journal of Haematology
https://read.qxmd.com/read/32779764/risk-factors-associated-with-progressive-increases-in-serum-creatinine-concentrations-in-cats-with-cancer-receiving-doxorubicin
#12
Lucy Kopecny, Carrie A Palm, Katherine A Skorupski, Mikel Delgado, Robert B Rebhun
BACKGROUND: Azotemia occurs in cats administered doxorubicin, but risk factors have not been explored. OBJECTIVE: To determine incidence of progressive increases in serum creatinine concentration in cats with cancer receiving doxorubicin in single or multiagent chemotherapy protocols and associated risk factors. ANIMALS: Seventy cats with cancer receiving doxorubicin. METHODS: A retrospective study (2007-2017) of cats with indices of kidney function recorded before and after doxorubicin administration was reviewed...
August 11, 2020: Journal of Veterinary Internal Medicine
https://read.qxmd.com/read/32779645/advancements-in-nanotechnology-for-the-diagnosis-and-treatment-of-multiple-myeloma
#13
REVIEW
Wenhao Zhong, Xinyu Zhang, Meng Zhao, Jun Wu, Dongjun Lin
Multiple myeloma (MM), known as a tumor of plasma cells, is not only refractory but also has a high relapse rate, and is the second-most common hematologic tumor after lymphoma. It is often accompanied by multiple osteolytic damage, hypercalcemia, anemia, and renal insufficiency. In terms of diagnosis, conventional detection methods have many limitations, such as it is invasive and time-consuming and has low accuracy. Measures to change these limitations are urgently needed. At the therapeutic level, although the survival of MM continues to prolong with the advent of new drugs, MM remains incurable and has a high recurrence rate...
August 11, 2020: Biomaterials Science
https://read.qxmd.com/read/32779615/clinical-application-of-genomic-aberrations-in-adult-t-cell-leukemia-lymphoma
#14
Keisuke Kataoka, Junji Koya
Adult T-cell leukemia/lymphoma (ATL) is an aggressive peripheral T-cell malignancy with a markedly poor prognosis. The low prevalence of ATL among human T-cell leukemia virus type-1 (HTLV-1) carriers and the long latency period before ATL onset suggest that additional genetic lesions are required for ATL leukemogenesis. Recently, a large-scale genetic analysis clarified the entire picture of genetic alterations, identified a number of novel driver genes, and delineated their characteristics. Frequent alterations are observed in the molecules belonging to T-cell receptor/NF-κB signaling and other T-cell-related pathways...
August 8, 2020: Journal of Clinical and Experimental Hematopathology: JCEH
https://read.qxmd.com/read/32779614/efficacy-of-oral-levofloxacin-monotherapy-against-low-risk-fn-in-patients-with-malignant-lymphoma-who-received-chemotherapy-using-the-chop-regimen
#15
Ai Mogi, Hidenori Sasaki, Yuta Nakashima, Shotaro Chinen, Masanao Ishizu, Toshihiro Tanaka, Tohru Takata, Yasushi Takamatsu
The safety and feasibility of oral fluoroquinolone monotherapy in patients with low-risk febrile neutropenia (FN) were demonstrated in recent studies. Levofloxacin (LVFX) is a commonly prescribed antibiotic; however, evidence for its efficacy against FN is limited. Therefore, in this study, we retrospectively investigated the efficacy of LVFX against low-risk FN in patients with malignant lymphoma at our institution. Treatment success was defined as recovery from fever and neutropenia without alteration of the initial regimen...
August 8, 2020: Journal of Clinical and Experimental Hematopathology: JCEH
https://read.qxmd.com/read/32779588/-a-case-of-difficult-to-diagnose-duodenal-gastrinoma
#16
Akie Kimura, Hiroko Nebiki, Nanako Yamaguchi, Naoto Hirata, Takehisa Suekane, Tomoaki Yamasaki, Koutarou Miura, Akihiro Murata, Hiroko Fukushima, Takeshi Inoue
A 42-year-old man, after remission of MALT lymphoma of the small intestine, was repeatedly hospitalized because of abdominal pain and severe dehydration caused by frequent vomiting and watery diarrhea. His symptoms would improve quickly every time when he was fasted and inserted a nasogastric tube. We were unable to find abnormalities on endoscopic examination and computed tomography. He was suspected to have gastrinoma because of active bleeding from a duodenal ulcer. High-level serum gastrin, endoscopic ultrasound, somatostatin receptor scintigraphy, and selective arterial calcium injection test were done...
2020: Nihon Shokakibyo Gakkai Zasshi, the Japanese Journal of Gastro-enterology
https://read.qxmd.com/read/32779406/circulating-epstein-barr-virus-dna-and-cell-free-dna-in-pediatric-lymphomas
#17
Bilgehan Yalçın, Tezer Kutluk, Serpil Kahraman Ağbaba, Çetin Demir, Beril Talim
BACKGROUND AND OBJECTIVES: Quantification of serum Epstein-Barr virus (EBV) DNA and/or cell-free total DNA (cf-DNA) may become valuable sources for prognosis evaluation and monitoring treatment response in lymphomas. We aimed to investigate their roles as potential markers in pediatric Hodgkin (HL) and non- Hodgkin lymphomas (NHL). METHOD: Between the years 2005-2008, 34 patients with HL and 45 with NHL were prospectively included. Serum samples were collected upon diagnosis, after 1-3 and 4-6 months and at the end of treatment, or at disease recurrence...
2020: Turkish Journal of Pediatrics
https://read.qxmd.com/read/32779387/r-chop-immunochemotherapy-plus-surgery-is-associated-with-a-superior-prognosis-in-chinese-primary-intestinal-diffuse-large-b-cell-lymphoma
#18
Fengyi Zhao, Yan Qin, Jianliang Yang, Peng Liu, Xiaohui He, Liqiang Zhou, Shengyu Zhou, Lin Gui, Haizeng Zhang, Xin Wang, Shiyu Jiang, Qiaofeng Zhong, Yu Zhou, Yuankai Shi
AIM: The aim of the study was to compare the therapeutic strategies and prognostic factors of patients with primary intestinal diffuse large B-cell lymphoma (PI-DLBCL). METHODS: A total of 50 PI-DLBCL patients who accepted standard first-line treatment at National Cancer Center in China were included in this retrospective study. Survival analysis was performed to evaluate the prognostic risk factors. RESULTS: The 3-year overall survival (OS) and 3-year progression-free survival (PFS) for the entire group were 76...
August 10, 2020: Asia-Pacific Journal of Clinical Oncology
https://read.qxmd.com/read/32779250/inflammatory-lobular-hemangioma-ilh-a-vascular-proliferation-with-a-prominent-lymphoid-component-review-of-a-series-of-19-cases
#19
Daniel Santa Cruz, Jose A Plaza, Mark R Wick, Alejandro A Gru
In the last 30 years, there has been a strong interest in vascular proliferations. Pyogenic granuloma was not only renamed lobular capillary hemangioma (LCH), but also the conceptual interpretation was also changed from an overgrowth of granulation tissue to a genuine hemangioma (or benign vascular neoplasm). We describe 19 cases of patients who presented clinically with a vascular lesion, characteristically a pyogenic granuloma or lobular hemangioma, where the histopathological findings lead to the pathologic concern for a lymphoma of the skin...
August 10, 2020: Journal of Cutaneous Pathology
https://read.qxmd.com/read/32778827/a-peripheral-immune-signature-of-responsiveness-to-pd-1-blockade-in-patients-with-classical-hodgkin-lymphoma
#20
Fathima Zumla Cader, Xihao Hu, Walter L Goh, Kirsty Wienand, Jing Ouyang, Elisa Mandato, Robert Redd, Lee N Lawton, Pei-Hsuan Chen, Jason L Weirather, Ron C J Schackmann, Bo Li, Wenjiang Ma, Philippe Armand, Scott J Rodig, Donna Neuberg, X Shirley Liu, Margaret A Shipp
PD-1 blockade is highly effective in classical Hodgkin lymphomas (cHLs), which exhibit frequent copy-number gains of CD274 (PD-L1) and PDC1LG2 (PD-L2) on chromosome 9p24.1. However, in this largely MHC-class-I-negative tumor, the mechanism of action of anti-PD-1 therapy remains undefined. We utilized the complementary approaches of T cell receptor (TCR) sequencing and cytometry by time-of-flight analysis to obtain a peripheral immune signature of responsiveness to PD-1 blockade in 56 patients treated in the CheckMate 205 phase II clinical trial (NCT02181738)...
August 10, 2020: Nature Medicine
keyword
keyword
958
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"